Unicycive Therapeutics

UNCY · NASDAQ

$3.80+$0.29 (+8.26%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $3.51

UNCY analyst rating

BuyConsensus of 6 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy6
Hold0
Underperform0
Sell0

12-month price target · 12 analysts

Average $28.97 (+662.3% upside)

Low: $13.13
Now: $3.80
High: $44.10

Upgrades and downgrades

The latest rating actions, newest first

UNCY analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Sep 29, 2026	Maintains	Buy	$15.00 → $13.00	43%
Benchmark	Aug 20, 2026	Maintains	Speculative Buy	$13.00 → $15.00	32%
Guggenheim	Aug 13, 2026	Maintains	Buy	$37.00 → $25.00	66%
B. Riley Securities	Aug 13, 2026	Maintains	Buy	$22.00 → $20.00	47%
Benchmark	Jul 1, 2026	Maintains	Speculative Buy	$18.00 → $13.00	32%
Noble Capital Markets	Jul 1, 2026	Maintains	Outperform	$60.00 → $50.00	28%
HC Wainwright & Co.	Jun 30, 2026	Maintains	Buy	$22.00 → $15.00	43%
B. Riley Securities	Jun 30, 2026	Maintains	Buy	$22.00	47%
Benchmark	Jun 2, 2026	Maintains	Speculative Buy	$15.00 → $18.00	32%
Guggenheim	May 13, 2026	Maintains	Buy	$40.00 → $37.00	66%

The case for and against

Updated Oct 16, 2026

Bull case

Unicycive Therapeutics is viewed favorably because the core risk behind OLC’s second Complete Response Letter appears regulatory and manufacturing-related rather than clinical, since the FDA raised no concerns about efficacy or safety and requested no additional data. The company also has a meaningful commercial catalyst in TDAPA, which could allow OLC to be reimbursed at 100% of ASP for two years outside the ESRD bundle, while cash and cash equivalents of $61.4M as of June 30, 2026 support operations into 2027. Even with modestly higher R&D at $2.79M and SGA at $7.35M in 2Q 2026, a successful vendor inspection could unlock approval, resubmission, and a large dialysis-market opportunity with peak OLC sales modeled near $800M in 2029.

Bear case

Unicycive Therapeutics is viewed negatively because it remains a clinical-stage company with no product revenue and a long history of operating losses, leaving it dependent on external financing while it builds pre-commercial infrastructure and a sales force ahead of a potential OLC launch. Its valuation and future cash generation hinge on binary regulatory and manufacturing outcomes for OLC, and even after approval, adoption risks, restrictive reimbursement dynamics, competition from generic binders, and possible label or REMS limitations could materially reduce commercialization potential. Financially, the company had about $61M in cash at the end of 2Q 2026, commitments for $102M through warrant tranches, potential dilution of up to 15.8M shares, and no expectation of continuing profitability until 2027.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.